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Some subgroups of patients with advanced/metastatic non-small-cell lung cancer (NSCLC) are frequently considered ineligible for the
aggressive, platinum-based combination chemotherapy that is the recommended treatment. Elderly patients may have a poorer
tolerance of chemotherapy due to impaired organ function and frequent comorbidities; patients with poor performance status (PS;
X2 due to NSCLC and/or coexisting illnesses) are often considered unfit for chemotherapy; other patients may be unable or
unwilling to endure the toxicity or inconvenience of chemotherapy. These patient groups may benefit from novel, relatively nontoxic
treatment modalities. Gefitinib (‘Iressa’, ZD1839) 250mg day1 is well tolerated and has proven antitumour and symptom
improvement activity in patients with previously treated NSCLC. Phase II trials (IDEAL 1 and 2) of gefitinib in advanced/metastatic
NSCLC included 70 out of 425 (16.5%) patients with PSX2, and their response rate, clinical benefit rate and rates of adverse events
were similar to those of the overall trial population. In addition, many patients with advanced/metastatic NSCLC with poor PS or
advanced age have received gefitinib 250mg day1 in an Expanded Access Programme (EAP). Observations from the EAP support
those of IDEAL 1 and 2, and indicate that gefitinib 250mg day1 warrants further investigation in these patient groups.
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Current standard combination chemotherapy regimens for ad-
vanced non-small-cell lung cancer (NSCLC) are effective in
prolonging survival, preventing or reducing tumour-related
symptoms and maintaining quality of life (Schiller, 2001). Given
the equal effectiveness of current regimens, the selection of therapy
for an individual patient is mainly based on the issue of side effects
and the ease of administration in a given setting.
Many patients, including the elderly and unfit, cannot be
considered eligible for combination chemotherapy in order to
avoid undue toxicity. In Europe, 430% of patients with NSCLC
are aged470 years (Gridelli, 2002), and patients in this age group
frequently experience a progressive decline in organ function. In
addition, many patients with NSCLC have multiple comorbidities
that impact on their performance status (PS), and other patients
are too ill because of symptoms from advanced disease, such as
weight loss, cough and fatigue (Govindan, 2003). Advanced age
and poor PS are factors that need to be considered when choosing
therapy.
Platinum-based combination chemotherapy can be associated
with high rates of severe adverse effects, including haematological
adverse events. Grade 4–5 events occurred in 57–70% of patients
in a large study (n¼ 1146) comparing four chemotherapy
regimens (cisplatinþ paclitaxel, cisplatinþ gemcitabine, cispla-
tinþ docetaxel and paclitaxelþ carboplatin) in patients with
advanced NSCLC (Schiller, 2001). In patients with NSCLC and a
PS of 2 (n¼ 64), a comparative study found grade 3–4
haematological toxicities in 450% of patients in each of four
treatment groups (paclitaxelþ cisplatin, cisplatinþ gemcitabine,
cisplatinþ docetaxel and paclitaxelþ carboplatin) (Sweeney et al,
2001). While it is generally accepted that haematological toxicity is
largely a laboratory toxicity, grade 4 febrile neutropenia does occur
in 3–14% of patients, depending on the regimen chosen (Schiller,
2001). Therefore, a proportion of elderly patients and patients with
poor PS are often considered ineligible for aggressive, platinum-
based combinations. In addition, second-line treatment options
are limited, and only patients with good PS are considered
candidates for second-line treatment.
Patients excluded or deterred from active therapy for advanced
NSCLC may benefit from new medications that are easy to take,
cause limited adverse events and have a low risk of drug
interactions. Alternative strategies need to be explored with the
aim of specifically tailoring therapy to the needs of these groups.
Novel, biologically targeted agents that aim to disrupt specific
properties of a tumour’s activities, while interfering with host
functions to a relatively minor degree, promise a higher
therapeutic margin and lower toxicity than traditional therapies.
One such agent, the epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) gefitinib (‘Iressa’, ZD1839) presents
new possibilities for patient groups considered unfit for aggressive
chemotherapy.
Gefitinib monotherapy in patients with advanced NSCLC has
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trials, ‘Iressa’ Dose Evaluation in Advanced Lung cancer (IDEAL) 1
and 2. The majority of patients in IDEAL 2 were receiving gefitinib
as at least fourth-line therapy, while it was second- or third-line
therapy for all of the patients in IDEAL 1. The objective tumour
response rate at 250mg day1 in IDEAL 1 was 18.4%. In IDEAL 2,
the more heavily pretreated trial population, the objective response
rate was 11.8% for the 250mg day1 dose. Objective responses
were seen irrespective of the number of prior chemotherapy
regimens. In addition, gefitinib was found to improve NSCLC-
specific symptoms at comparable rates in the two trials (40.3 and
43.1% of patients in IDEAL 1 and 2, respectively) (Douillard et al,
2002; Natale et al, 2002). Adverse events at the 250mg day1 dose
were generally mild and reversible grade 1/2 (National Cancer
Institute common toxicity criteria (CTC) version 2.0) diarrhoea
and skin reactions (rash, pruritus, dry skin, acne), with a low
incidence of grade 3/4 adverse drug reactions, dose reductions and
withdrawals due to drug-related adverse events (Herbst and Kies,
2002; Kris et al, 2003). Gefitinib was not associated with
haematological toxicity or stomatitis. Overall, the results showed
that 250mg day1 gefitinib was as effective as 500mg day1, and
the superior tolerability of 250mg day1 makes this the recom-
mended dose (Fukuoka et al, 2003; Kris et al, 2003).
Recently, data became available from centres that have
administered gefitinib 250mg day1 to patients with advanced
NSCLC on a compassionate-use basis, as part of an Expanded
Access Programme (EAP). The Iressa Clinical Experience (ICE)
meeting of investigators held in Madrid, Spain (June 2003) allowed
clinicians to share their experience of gefitinib in patient groups
that included the elderly and unfit as well as patients unwilling to
tolerate chemotherapy. Some of these patients received gefitinib
250mg day1 as first-line therapy. This paper brings together
results from IDEAL 1 and 2 and from the EAP, and discusses
treatment approaches for groups of patients with special therapy
requirements.
CURRENT APPROACHES TO SPECIAL PATIENT
POPULATIONS WITH NSCLC, AND CLINICAL
EXPERIENCE FROM THE GEFITINIB EAP
Patients with poor PS (X2)
Studies have shown that PS at diagnosis is a powerful prognostic
indicator in patients with NSCLC. For several types of treatment,
poor PS has been associated with reduced survival, poor response
rate or increased toxicity. In a study involving patients with
NSCLC treated with docetaxel, patients with PS 0–1 had a median
overall survival of 11.3 months compared with 3.8 months for
patients with PS 2 (Po0.0001) (Kosmidis et al, 1997). A further
study, comparing combination chemotherapy (paclitaxelþ
carboplatin vs paclitaxelþ gemcitabine), found that patients with
PS 2 had a lower response rate (11%) than patients with PS 0–1
(34%) (Po0.0001) (Kosmidis et al, 2002). In ECOG study E1594,
comparing paclitaxel and cisplatin with three other chemotherapy
doublets in patients with advanced NSCLC, patients with PS 2
experienced a large number of adverse reactions and overall poor
survival. In the course of the trial, accrual of patients with PS 2 was
discontinued due to a perceived rate of unacceptable toxicity that
was judged to be related to the disease process rather than
treatment (Sweeney et al, 2001). Taken together, the results of
these studies support the view that patients with poor PS have
special treatment requirements.
Based on current data and treatment options, a recent European
consensus panel recommended single-agent chemotherapy (e.g.
gemcitabine, vinorelbine, taxanes) as the preferred first-line
treatment for patients with advanced NSCLC and PS X2, with
carboplatin-based doublets or attenuated-dose cisplatin-based
doublets as alternatives).
Experience with gefitinib Phase II trials (IDEAL 1 and 2) of
gefitinib in advanced/metastatic NSCLC included 70/425 (16.5%)
patients with PS X2. The majority (43 out of 70) of these were in
IDEAL 2, where they formed 19.9% of the overall population. The
efficacy of gefitinib in patients with PS X2 in IDEAL 2 was
comparable with its efficacy in IDEAL 2 overall: patients with PS
2–3 had a response rate of 14% and a clinical benefit rate ofB40%
compared with rates in the whole trial population of 11.8 and
42.2%, respectively.
At the SG Moscati Hospital, Avellino, Italy, 41 patients with PS
X2 have been treated with gefitinib 250mg day1 as part of the
gefitinib EAP (Gridelli et al, 2003; Gridelli [a], ICE abs). (See
appendix for ICE abstracts.) Patient characteristics are shown in
Table 1. From 39 evaluable patients, two patients with adenocarci-
noma reported a partial response (PR) and five patients had stable
disease (SD), giving a disease control rate of 17.1%. The most
frequent adverse events were grade 1 diarrhoea in two patients and
grade 2 elevation of liver transaminases in one patient. One female
patient with brain metastases had a complete response (CR) in the
brain (Maione, ICE abs). This patient had received two prior
chemotherapy regimens and radiotherapy, and had a PS of 3 prior
to gefitinib treatment. After beginning to take gefitinib
(250mg day1) the patient became stable and after 2 months, her
PS had improved to 1; CR in the brain was documented after 3
months. The patient continued to be stable at the time of reporting
(April 2003), and had experienced no adverse events.
In all, 25 abstracts presented at this EAP investigators’ meeting
discussed 475 patients with poor PS. Clinical benefit in the form
of objective response, stable disease or improved PS was described
in many cases, with generally good tolerability. Notably, a
complete response was seen in a 39-year-old patient, with no
history of smoking, who had undergone three prior cycles of
chemotherapy and had a PS of 2. The patient’s PS returned to 0
after 8 weeks of gefitinib 250mg day1, and the patient remained
on gefitinib therapy for 52 weeks, experiencing a mild treatment-
related acneiform rash at week 2 that had decreased by week 7
(Gelibter, ICE abs). In another report, a patient with bronchioal-
veolar cell carcinoma and a PS of 2–3 experienced a PR lasting for
9 months, during which time the PS returned to 1. Adverse events
comprised mild diarrhoea and intermittent skin rash (van
Zandwijk [a], ICE abs). A further report detailed a patient with
PS 4 who experienced a 2-month period of disease and symptom
control while taking gefitinib, with no side effects (Vincent,
ICE abs).
In addition to these reports, an interim analysis of EAP patients
with PS 2–3 in the USA has shown a response rate of 13% and a
clinical benefit rate of B30% (Wolf et al, 2003). In summary,
gefitinib treatment was feasible and well tolerated in patients with
PS X2 treated in the EAP, producing objective responses and
Table 1 Demographics of a group of patients with NSCLC and poor PS
treated with gefitinib 250mg day1 in an EAP (Maione, ICE abs; Gridelli
et al, 2003). Reproduced with permission.
Patients, n 41
Male : female, n 26 : 15
Median age (range) (years) 60 (38–69)
Disease stage, n
IIIb 4
IV 37
Eastern Cooperative Oncology Group
performance status 2/3, n 29/12
Tumour histology, n
Squamous-cell carcinoma 17
Adenocarcinoma 21
Undefined 3
Prior chemotherapy regimens, n
0/1/X2 1/16/24
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disease control rates that were comparable to those seen in IDEAL
1 and 2. Durable responses were seen in heavily pretreated patients
with poor PS.
Elderly patients
For elderly patients with advanced NSCLC, single-agent chemo-
therapy remains the standard treatment approach (Gridelli, 2002).
However, many elderly patients with good PS are considered
unsuitable for chemotherapy because of reduced organ function.
In IDEAL 1 and 2, patients taking gefitinib had ages that ranged up
to 85 and 84 years, respectively, and elderly patients formed a
considerable proportion of the patients that were evaluated for
efficacy and tolerability. Although no analyses have been carried
out on these patients specifically, relevant data have been
forthcoming from reports presented at the ICE meeting, including
two reports that together detail 39 patients (Table 2) (Gridelli et al,
2003; Gridelli [a], ICE abs; Soto Parra et al, 2003; Soto Parra [b],
ICE abs). Disease control was seen in both studies (SD in two
patients and 16 patients, respectively). In one of the studies (Soto
Parra et al, 2003), the median survival was 4 months and 1-year
survival was 26%. Disease control was seen in 450% of elderly
patients, and patients with disease control tended to have
improved median survival (Figure 1). The most common adverse
events were skin rash (grade 1–2 in 42%; grade 3 in 10% of
patients) and diarrhoea (grade 1–2 in 29%; grade 3 in 3% of
patients).
Overall, gefitinib 250mg day1 showed reasonable efficacy and
mild toxicity in these studies, and appears to be a valuable
treatment option for elderly patients. Many other case reports
from the EAP supported these findings.
Chemonaive patients
Many patients with advanced NSCLC, including the elderly or
unfit, are unable or unwilling to tolerate chemotherapy. Several
cases of chemonaive patients treated with gefitinib 250mg day1 as
part of the EAP were discussed by investigators.
Petruzelka et al (ICE abs [b]) described a patient who chose not
to receive chemotherapy as first-line treatment: a 64-year-old male
exsmoker who presented with palpably enlarged lymph nodes in
the right supraclavicular area. The supraclavicular mass was
removed by nonradical surgery, and epidermoid carcinoma was
confirmed by histopathology. Computed tomography scanning
and X-ray imaging diagnosed a primary tumour in the right upper
lobe (February 2002), and multiple metastatic bone lesions were
also revealed. The patient was asymptomatic, but had several
coexisting conditions including hypertension, obesity, diabetes
mellitus, dyslipoproteinaemia and chronic obstructive pulmonary
disease. He refused standard chemotherapy and received radio-
therapy to the supraclavicular area (April-May 2002); he began to
take gefitinib 250mg day1 in July 2002. In August 2002, he had a
partial response (Figure 2), confirmed 2 months later, and after a
further 3 months he had regression of bone metastases (Figure 2)
and no rib lesions on scintigraphy. His PR lasted411 months, and
was ongoing at the time of reporting. Improved quality of life was
seen 2 months after starting gefitinib, which was generally well
tolerated (grade 1 skin rash and grade 1/2 conjunctivitis).
Pesek and Eliasova described the case of a 70-year-old female
nonsmoker who presented with stage IV pulmonary adenocarci-
noma, with metastases to both lungs, mediastinal lymph nodes and
vertebral column, and left-sided malignant pleural effusion (Pesek
and Eliasova, ICE abs). She had severe comorbidity including
cough, chest pain and fever, and a Karnofsky PS of 70%. She was
offered standard first-line combination chemotherapy, but refused
due to anxiety. She began gefitinib 250mg day1 2 months later.
Symptoms (cough, dyspnoea and chest pain) improved within 2
weeks of starting gefitinib, and the patient’s quality of life
improved. Nausea and diarrhoea were successfully managed, and
the patient recorded a best response of SD and remission of pleural
effusion. On tumour progression, the patient stopped gefitinib and
began combination chemotherapy with gemcitabine, paclitaxel and
carboplatin. A PR ensued, together with symptom improvement.
At the time of reporting, 30 months after diagnosis, the patient was
alive with slow, progressive, malignant disease.
These case reports show that gefitinib monotherapy can be
efficacious in chemonaive patients, and can cause sustained
responses at primary and metastatic sites, a finding that was
supported by other EAP investigators’ reports. In addition, it is
clear that chemotherapy can be effective as second-line therapy
following gefitinib.
Table 2 Demographics of two groups of elderly patients with NSCLC
treated with gefitinib 250mg day1 given in an EAP (Gridelli et al, 2003).
Rerpoduced with permission.
Investigators Gridelli et al (2003)
Soto Parra et al
(2003)
Patients, n 18 41
Male : female, n 17 : 1 26 : 15
Median age (range)
(years)
73.5 (70–80) 60 (38–69)
Disease stage, n 4
IIIb 3 37
IV 15
Eastern Cooperative
Oncology Group
performance status
1/2/3, n
4/11/3 All X1
Tumour histology, n
Squamous-cell
carcinoma
10 8
Adenocarcinoma 6 12
Bronchioalveolar 1 0
Undefined 1 11
Prior chemotherapy
regimens, n
0/1/X2 1/7/10 11/16/4
1.00
0.75
0.50
0.25
0
0 6 12 18 24
O
ve
ra
ll s
ur
viv
al
Patients with 
disease control
(n = 16)
All patients 
(n = 31)
Figure 1 Kaplan–Meier plot of overall survival in a group of 31 elderly
patients (mean (range) age 74 (70–82) years) with NSCLC taking gefitinib
250mg day1 as part of the gefitinib EAP at a centre in Rozzano, Italy (Soto
Parra et al, 2003).
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DISCUSSION
Data from the EAP show that, in elderly, unfit or chemonaive
patients, the tolerability profile of gefitinib appears to be similar to
that seen in the IDEAL trials and the general EAP population,
supporting further investigation of gefitinib in these patient
groups. The response rate with gefitinib in patients with PS 2–3
was 14% in IDEAL 2 and 13% in an interim analysis of the EAP.
Despite the inclusion of many elderly (up to 85 years) patients in
IDEAL 1 and 2, and inclusion of many patients with PSX2 (12.9%
in IDEAL 1 and 19.9% in IDEAL 2), 1-year survival was
approximately 30%. This compares favourably with data from
the IDEAL and EAP populations as a whole, and with data from a
previous study for a population with similar baseline pretreatment
characteristics: following initial regimens of a platin and docetaxel,
patients (n¼ 43) with a mean age of 51 (range 20 – 80) years went
on to undergo subsequent lines of chemotherapy as required.
Although 495% of patients had PS 0–1, 1–year survival was
approximately 5%, and median survival was 4 months (Massarelli
et al, 2002).
Case reports and case cohorts show that several elderly or unfit
patients have experienced significant clinical benefit. However,
defining the most appropriate patient groups for first-line gefitinib
treatment raises questions that have yet to be answered. Ideally,
clinical trials are needed to quantify benefits and inform treatment
choices. Several ongoing clinical trials are investigating gefitinib in
special patient populations in NSCLC. These include (i) an open
Phase II study of gefitinib plus best supportive care in chemonaive
patients considered ineligible for chemotherapy with advanced
NSCLC; (ii) a Phase II trial of single-agent gefitinib in poor-PS
patients with previously untreated advanced NSCLC; (iii) a Phase I
trial of gefitinib tolerability in combination with irradiation with
or without cisplatin in patients with inoperable stage III NSCLC;
and (iv) a multicentre, randomised Phase II study of gefitinib and
gemcitabine vs gefitinib and vinorelbine as first-line therapy for
elderly patients with advanced NSCLC. Prior to the design of future
trials, a retrospective analysis of current data could be informative,
to assess the reasons for administering gefitinib in chemonaive
patients and to allow stratification of patients according to PS and
comorbidities.
Taken together, the data from IDEAL and the EAP suggest
several important benefits for patient groups with special needs,
and present a compelling case for further investigations of gefitinib
in these groups. It is hoped that data will continue to emerge from
the EAP to complement the findings of clinical trials, as well as
informing the planning of future trials that will accurately define
the scope of gefitinib monotherapy in NSCLC patient subgroups.
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